Is it worth investing?
Pfizer Inc is a middle-of-the-road business, at a price that demands patience.
Pfizer Inc (PFE) is a company in the Drug Manufacturers - General industry, listed on NYSE, with a market capitalisation of 146 billion USD. The stock trades at 25.60 USD, 10% below its 52-week high.
Against trailing twelve-month earnings, the price asks 19.5 times profit, versus 19.2 times for the industry median. Return on equity stands at 8.6%, against an industry median of 21.9%. Revenue has grown 8.5% a year over the past five years.
Over the past twelve months the stock returned +16.8%, against +24.8% for SPY over the same period. The analysis below covers valuation, profitability, growth, the balance sheet and price behaviour, with data updated daily.
Key data
The reported figures, before any interpretation
Price and Trading
- Open The price at which Pfizer Inc shares first traded in the latest session.
- Close The price of the last Pfizer Inc trade in the session that closed.
- Day range The lowest and highest price Pfizer Inc shares reached in that session.
- Volume How many Pfizer Inc shares changed hands in the latest session.
- 52-week range The lowest and highest price of Pfizer Inc shares over the past year.
- Position in the 52-week range Where the current price of Pfizer Inc shares sits between the low and the high of the past year. 100% means right at the high.
- 50-day average The average price of Pfizer Inc shares over the last 50 sessions. Shows the short-term trend.
- 200-day average The average price of Pfizer Inc shares over the last 200 sessions. Shows the long-term trend.
- Market cap The market value of all Pfizer Inc shares combined.
Earnings and Valuation
- Earnings per share How much net profit belongs to a single Pfizer Inc share over the last twelve months.
- Estimated earnings, current year The earnings per share analysts expect from Pfizer Inc for the current financial year.
- Estimated earnings, next year The earnings per share expected from Pfizer Inc for the following financial year.
- Revenue per share How much of the annual sales of Pfizer Inc belongs to a single share.
- Book value per share How much Pfizer Inc equity belongs to one share, once debt is subtracted from assets.
- Revenue, last 12 months Total Pfizer Inc sales across the last four reported quarters.
- Price / earnings How many years of current profit a Pfizer Inc share costs at today price.
- Forward price / earnings The same ratio, but against the profit Pfizer Inc is expected to make next year.
- PEG The price/earnings ratio of Pfizer Inc divided by its growth rate. Below 1 is considered cheap relative to how fast it grows.
- Enterprise value / EBITDA The price of the whole Pfizer Inc business, debt included, against operating profit before depreciation.
Return and Risk
Low risk · 67- Net margin How much net profit Pfizer Inc keeps out of every unit of sales.
- Return on equity How much net profit Pfizer Inc produces from shareholder money.
- Dividend yield How much Pfizer Inc pays out in dividends each year, relative to the share price.
- Dividend per share The estimated annual amount received for each Pfizer Inc share held.
- Payout ratio What share of Pfizer Inc profit goes back to shareholders as dividends. The rest stays in the company.
- Beta How strongly Pfizer Inc shares move against the market. 1 means the same, above 1 means wider swings.
- Debt / equity How much debt Pfizer Inc carries for every unit of equity.
- Short interest as % of float What share of freely tradable Pfizer Inc stock is sold short, as a bet on a decline.
- Days to cover short positions How many normal trading days it would take to close every short position on Pfizer Inc.
Some values update after the trading session opens, others are recalculated after it closes. Figures from the financial statements change only when results are published.
Verdict
The Pfizer Inc score from 0 to 100, built from over 400 financial indicators. Not investment advice.At Pfizer Inc, return on capital exceeds its cost.
Earnings per share fell 37% a year over the past three years.
Revenue has fallen 15% a year over three years. Free cash flow covers 7% of the price each year. Net margin has fallen to 11.8%, from a five-year average of 17.4%.
- In Healthcare, Pfizer Inc is above the sector average on shareholder yield and stability, below it on growth.
- attractive verdicts returned a median of +18.6% over one year, across 18,397 assessments.
Analysis produced automatically by einvestitii.ro, on data as of aug. 24, 2026. It is not investment advice. Who produces it, what it rests on and what conflicts of interest exist — in the full disclosure.
Arguments for and against
What supports the case and what weakens it
Pro 8 arguments
- 💵The dividend yields 6.7% a year against the price.The risk-free rate in US is 4.7% — here you get comparable, plus exposure to the company's growth.
- 💰The net margin at Pfizer Inc is 11.8%, above the typical company in the sector.The sector median is 8.2%.
- ⚖️Today's buyer pays for 19.5 years of current earnings.Below the sector median, which asks 19.5 years.
See all 8
- 🛡The bankruptcy model places the company in the safe zone.The Altman score is 6.31, against the 2.60 threshold below which the risk zone starts.
- 🔥The 50-day price average sits above the 200-day.The opposite of the warning setup. The price sits 2.0% above the long average.
- 💰Each unit reinvested produces more than it costs.Return on capital is 6.8%, its cost 5.4%. Growth adds value.
- 🛡Short-selling pressure is minimal.Only 2.0% of the free float is sold short, and covering would take 3.98 days.
- 📈Institutions were net buyers last quarter: 15 funds added, 8 trimmed.Together they hold 69.4% of the company.
Against 4 arguments
- 🏦Debt is 3.98 times annual operating profit.Above the sector median of 1.5. A weak stretch leaves less room to manoeuvre.
- Each unit of shareholder capital produces only 8.6% of profit a year.The typical company in the sector produces 10.5%.
- 🧊Revenue grew 8.5% a year over the past five years.Below the typical company in the sector, which grew 9.2%.
See all 4
- No barrier is identified that keeps competitors at bay.Without a durable edge, margins depend on execution, not position.
What it is really worth
Value & Valuation
The market price is what buyers are asking today. Here we work out what the share should cost based on the company’s own figures: using the valuation models professional investors rely on, the growth the current price assumes, and the target set by the analysts who follow the company.
what analysts think
What the analysts covering the company think, and where they see the price twelve months out. These are their estimates, not ours.
- Strong sell 1 4%
- Sell 0 0%
- Hold 15 60%
- Buy 2 8%
- Strong buy 7 28%
The analyst consensus is in line with our score.
Analyst estimates, third-party source. These are not our verdict.
-
Price today $25.60
-
Revisions, last 30 days 12 ↑8 ↓
-
Expected earnings growth -4.21%
-
Analysts covering 25
Analyst estimates, third-party source.
fair value
Slightly overvalued price $25.60the price is 1.5 times the estimate from 5 models
What Pfizer Inc shares should cost, according to the valuation models of the best-known investors in history.
These are estimates, not price targets: every model starts from assumptions about the future, and if the assumptions change, so does the number.
- Median of 5 modelsNot the average, but the middle value. A model that falls far out of line does not drag the result with it.
- Confidence in the estimateHow close the models are to one another.
- Spread across modelsHow far they deviate from the median on average. Below 50% means they are reasonably close.
- Growth the price demandsHow fast profit would have to grow, year after year, for today’s price to make sense.
- Growth actually deliveredThe average growth of past years. Compare it with the line above.
5 different methods, the same company figures. Each assumes something different about the future, and that is where the differences come from.
For today’s price to be justified, earnings would have to grow -2.7% a year. Over the past five years they grew -3.4%.
- Growth the price requiresThe annual pace earnings would have to reach for today’s price to be justified.
- Growth actually deliveredHow much earnings per share actually grew over the past five years.
- The gapHow far above past performance the expectation in the price sits.
- Value with no growthWhat the company would be worth if it stayed exactly as it is today.
Starting from a base value of $28.98, how much the result changes if you alter each assumption in turn.
The cost of capital moves the estimate almost three times as much as earnings growth.
projections
Projection computed on 18 august 2026These are not predictions. The model splits the possible outcomes into ranges and reports how often the price landed in each, across similar cases in the past.
-
12 months out · median +3,4% −31% … +48%
-
3 years out, per year · median +5,6% +0% … +8%
-
5 years out, per year · median +5,1% +0% … +7%
-
Of which repricing, per year −5,0%
Quantiles of a probabilistic model. Not price targets.
- Higher than today's price 60%
- Better than the index 47% index +4,5%
- Gain over 20% 18%
- Drop over 10% 20%
- Drop over 20% 9%
If the market fell 20%, the model expects −11,6% for this stock — because it moves 0,55 times as hard as the market. On a 40% fall: −23,2%.
Probabilities verified on historical cases.
profitability
return on capital 6.77%The engine runs at middling speed
The gap of 1.38% has held in each of the last 15 years.
- net margin11.83%
- consecutive revenue growth15 years
growth
revenue, 3 years -14.56%The pace has slowed
balance sheet and dividends
Solid balance sheet
- net debt$62.75B
- dividend yield6.65%
- of returned capital goes to buybacks2.11%
Middling quality
and a stretched price.
Neither the business nor the price stands out. This is a case decided on details, not on the big picture.
For this to work out, the growth rate would have to resume, not merely stabilise.
Disclosure (legal information) See details Hide
Analysis produced by einvestitii.ro, founder . We are not supervised by the Romanian Financial Supervisory Authority. This is not personalised investment advice. Fair values are estimates, not guaranteed prices.
- Calculated 24 August 2026
- Price used $25.60 (as of 10 June 2026)
- Estimated fair value $17.55 — an estimate dependent on assumptions (cost of capital, growth, terminal value). Not a price target. Confidence: Medie.
- Updates On every recalculation of the company fundamentals.
- Verdict changed no (score +4.2 against the previous assessment)
- Conflicts of interest We hold no positions in the instruments analysed and receive no payment from issuers for assessments. Pages may contain affiliate links to brokers, marked as such, which do not influence the scores.